Fol­low­ing con­tro­ver­sial Aduhelm ap­proval, DC-based neu­rol­o­gy cen­ter bans Bio­gen rep­re­sen­ta­tives from its of­fices — re­port

CEO Michael Vounatsos con­fessed ear­li­er this month that Bio­gen was strug­gling to get its con­tro­ver­sial new Alzheimer’s drug Aduhelm off the ground, with some ma­jor health sys­tems re­fus­ing to ad­min­is­ter it.

Now, a DC-based med­ical cen­ter is tak­ing its small re­bel­lion against the drug’s ap­proval one step fur­ther.

The Neu­rol­o­gy Cen­ter has re­port­ed­ly banned all Bio­gen rep­re­sen­ta­tives from its sev­en DC-area of­fices, ac­cord­ing to a pho­to cir­cu­lat­ing on Twit­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER